

THERAVANCE INC  
Form 8-K  
November 25, 2008

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**Current Report Pursuant  
to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): **November 21, 2008**

---

**THERAVANCE, INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**000-30319**  
(Commission File Number)

**94-3265960**  
(I.R.S. Employer Identification Number)

**901 Gateway Boulevard**  
South San Francisco, California 94080  
(650) 808-6000

## Edgar Filing: THERAVANCE INC - Form 8-K

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On November 21, 2008, Theravance, Inc. ( Theravance ) entered into an amendment to the Amended and Restated Rights Agreement between Theravance and The Bank of New York Mellon Corporation (formerly known as The Bank of New York ) dated June 22, 2007 (the Rights Agreement ). This amendment to the Rights Agreement increases from 15% to 19% the threshold percentage ownership of Theravance s outstanding Common Stock necessary to cause a person or group to become an Acquiring Person under the Rights Agreement and thereby trigger the issuance of rights under the Rights Agreement.

The foregoing description of the amendment to the Rights Agreement is qualified in its entirety by reference to the full text of the amendment, attached hereto as Exhibit 4.1 and incorporated herein by reference.

**Item 3.03 Material Modification to Rights of Security Holders.**

The description of the amendment to the Rights Agreement set forth above under Item 1.01 is incorporated herein by reference.

**ITEM 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit</b>	<b>Description</b>
Exhibit 4.1	Amendment to Rights Agreement dated November 21, 2008 between Theravance, Inc. and The Bank of New York Mellon Corporation (formerly known as The Bank of New York )

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**THERAVANCE, INC.**

Date: November 25, 2008

By:

*/s/ Michael W. Aguiar*

**Michael W. Aguiar**  
**Chief Financial Officer**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Exhibit</b>
4.1	Amendment to Rights Agreement dated November 21, 2008 between Theravance, Inc. and The Bank of New York Mellon Corporation (formerly known as The Bank of New York )